Mandate

Vinge advises Hansa Medical in connection with directed share issue

November 30, 2017 Capital Markets and Public M&A

The board of directors of Hansa Medical has resolved on a directed new issue of ordinary shares, subject to approval by an extraordinary general meeting, whereby Hansa Medical will raise proceeds of approximately SEK 545 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable long-only investors and international sector specialist funds, on the basis of an accelerated bookbuilding process conducted by Evercore, RBC Capital Markets and SEB.

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Dain Hård Nevonen, Erik Sjöman, Joakim Hagberg, Sabina Börjesson and Ramin Baradaran.

Related

Vinge advises Lagercrantz Group in conjunction with the acquisition of Stalon

Lagercrantz Group Aktiebolag has acquired 88 per cent of the shares in Stalon AB, a Swedish manufacturer of silencers for hunting firearms. The company is based in Stalon, which is located outside Vilhelmina, where the company conducts development and production in its own facilities.
May 21, 2026

Vinge advises PPI Public Property Invest AB (publ) in connection with cross-border merger and listing on Nasdaq Stockholm and Euronext Oslo Børs

Vinge has advised PPI Public Property Invest AB (publ) (“PPI”) in connection with its listing on Nasdaq Stockholm and secondary listing on Euronext Oslo Børs. The listing was carried out through a cross-border merger whereby PPI absorbed Public Property Invest ASA, whose shares were previously listed on Euronext Oslo Børs.
May 20, 2026

Vinge represents Triton in connection with the sale of Aleris

Vinge has represented Triton in connection with the sale of Aleris to Mehiläinen Group.
May 18, 2026